Daniel Curran
Director/Board Member chez XILIO THERAPEUTICS, INC.
Profil
Dr. Daniel Curran is an Independent Director at Xilio Therapeutics, Inc. He is on the Board of Directors at Oak Hill Bio Corp., Xilio Therapeutics, Inc., Stargazer Pharmaceuticals, Inc. and Tome Biosciences, Inc. Dr. Curran was previously employed as a Senior VP, Head-Rare Genetics & Hematology by Takeda Pharmaceutical Co., Ltd., a Vice President-Business & Corporate Development by Takeda Oncology Co., and a Principal by DuPont Merck Pharmaceutical Co. He received his undergraduate degree from King's College (Pennsylvania), an MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from the University of Pennsylvania Medical Center.
Postes actifs de Daniel Curran
| Sociétés | Poste | Début |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Director/Board Member | 01/12/2020 |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Director/Board Member | 01/01/2019 |
Oak Hill Bio Corp.
 Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Director/Board Member | 12/04/2022 |
Tome Biosciences, Inc.
 Tome Biosciences, Inc. BiotechnologyHealth Technology Tome Biosciences, Inc. provides genomic medicine insertion and technologies services. The company is based in Cambridge, MA. The CEO of the company is Rahul Kakkar. | Director/Board Member | - |
Anciens postes connus de Daniel Curran
| Sociétés | Poste | Fin |
|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/10/2012 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | - |
Formation de Daniel Curran
| King's College (Pennsylvania) | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania Medical Center | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Health Technology |
Tome Biosciences, Inc.
Tome Biosciences, Inc. BiotechnologyHealth Technology Tome Biosciences, Inc. provides genomic medicine insertion and technologies services. The company is based in Cambridge, MA. The CEO of the company is Rahul Kakkar. | Health Technology |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Commercial Services |
